- Home
- CFBK vs XFOR Comparison
CFBK vs XFOR Comparison
Compare CFBK & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- XFOR
- Stock Information
- Founded
- CFBK 1892
- XFOR 2014
- Country
- CFBK United States
- XFOR United States
- Employees
- CFBK N/A
- XFOR N/A
- Industry
- CFBK Major Banks
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CFBK Finance
- XFOR Health Care
- Exchange
- CFBK Nasdaq
- XFOR Nasdaq
- Market Cap
- CFBK 127.9M
- XFOR 118.4M
- IPO Year
- CFBK 1998
- XFOR N/A
- Fundamental
- Price
- CFBK $23.94
- XFOR $3.40
- Analyst Decision
- CFBK Buy
- XFOR Strong Buy
- Analyst Count
- CFBK 1
- XFOR 3
- Target Price
- CFBK $29.00
- XFOR $72.33
- AVG Volume (30 Days)
- CFBK 22.9K
- XFOR 180.2K
- Earning Date
- CFBK 05-06-2025
- XFOR 05-01-2025
- Dividend Yield
- CFBK 1.17%
- XFOR N/A
- EPS Growth
- CFBK N/A
- XFOR N/A
- EPS
- CFBK 2.28
- XFOR 2.16
- Revenue
- CFBK $47,663,000.00
- XFOR $31,364,000.00
- Revenue This Year
- CFBK N/A
- XFOR $915.88
- Revenue Next Year
- CFBK N/A
- XFOR N/A
- P/E Ratio
- CFBK $10.49
- XFOR $1.57
- Revenue Growth
- CFBK 1.22
- XFOR N/A
- 52 Week Low
- CFBK $16.92
- XFOR $2.67
- 52 Week High
- CFBK $31.17
- XFOR $33.90
- Technical
- Relative Strength Index (RSI)
- CFBK 61.06
- XFOR 39.83
- Support Level
- CFBK $23.61
- XFOR $2.67
- Resistance Level
- CFBK $24.25
- XFOR $3.56
- Average True Range (ATR)
- CFBK 0.29
- XFOR 0.28
- MACD
- CFBK -0.07
- XFOR 0.21
- Stochastic Oscillator
- CFBK 48.51
- XFOR 82.02
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.